Potential treatment could prevent millions of annual heart failures and deaths in severe heart attack patients

A clinical trial in which cardiac patients received intravenous dexrazoxane before, during and after their blocked coronary artery was reopened showed a reduction in bleeding within the heart muscle, intramyocardial hemorrhage (IMH), in adults with a severe heart attack called ST-segment elevation myocardial infarction (STEMI). This trial was performed by clinical investigators from the Cardiovascular Imaging Research Center (CIRC) at Indiana University School of Medicine.

≈